
Revolution Medicines
OrganizationHeard in 17 episodes across 12 shows since Oct 2025
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering targeted medicines for patients with RAS-addicted cancers. Its pipeline includes RAS pathway inhibitors, including daraxonrasib (RMC-6236).
Episodes
This week
Expert statements
Share of the conversation
Mentions of Revolution Medicines per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 26 | 0.03‰ | 2 |
| Aug 28 | 0.03‰ | 1 |
| Sep 1 | 0.04‰ | 1 |
| Sep 13 | 0.02‰ | 2 |
| Oct 16 | 0.01‰ | 1 |
| Oct 20 | 0.02‰ | 1 |
| Oct 27 | 0.01‰ | 1 |
| Oct 30 | 0.03‰ | 2 |
| Nov 6 | 0.02‰ | 2 |
| Nov 9 | 0.03‰ | 2 |
| Nov 12 | 0.04‰ | 1 |
| Nov 13 | 0.03‰ | 1 |
| Nov 15 | 0.07‰ | 5 |
Email alert
Email me when Revolution Medicines comes up on a podcast
One email a week at most, with the new episodes that mention Revolution Medicines. Free, no account needed, unsubscribe in one click.
What experts have said about Revolution Medicines
11 statements · 9 positive · 2 negative
Revolution Medicines’ decline created an opportunity to buy shares.
“So it's down a little bit, but I saw it as an opportunity to take a long position.”
Open the episode · 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026Listen at 1:15
Revolution Medicines remains a pioneer in RAS-mediated cancer treatment.
“I still see RevMed as being, you know, the pioneer in RAS-mediated cancers.”
Open the episode · 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026Listen at 22:50
Revolution Medicines’ valuation does not fully reflect future upside.
“a $36 billion valuation is sort of pricing out some of the upside that I think is yet to come.”
Open the episode · 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026Listen at 23:07
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
17 episodes featuring Revolution Medicines, newest first
- Nov 15, 2026
Biotech investors weigh gene editing, MASH data and RAS riskBreaking BiotechNov 15, 2026 - Nov 13, 2026
Biotech launches expose the gap between forecasts and adoptionBiotech HangoutNov 13, 2026 - Nov 12, 2026
Biotech’s uncertainty creates disciplined investment opportunitiesThe Acquirers PodcastNov 12, 2026 - Nov 9, 2026
Biotech investors weigh obesity, RAS drugs and Moderna catalystsBreaking BiotechNov 9, 2026 - Nov 6, 2026
Election stakes meet biotech’s regulatory and pipeline risksBiotech HangoutNov 6, 2026 - Oct 30, 2026
Cancer vaccine data meets market volatility at ESMOThe Readout LoudOct 30, 2026